Previous 10 | Next 10 |
Debiopharm ( www.debiopharm.com ), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases , and Repare Therapeutics Inc. (“Repare”) (Nasdaq: RPTX), a leading clinical-stage p...
2024-04-26 16:18:41 ET More on Repare Therapeutics Repare to regain global rights to camonsertib from Roche Seeking Alpha’s Quant Rating on Repare Therapeutics Historical earnings data for Repare Therapeutics Financial information for Repare Therapeuti...
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Steven H. Stein, M.D., to its Board of Directors, effective as of the date of the Company’s upcoming annu...
NEW YORK, NY / ACCESSWIRE / March 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Repare Therapeutics Inc. ("Repare" or "the Company") (NASDAQ:RPTX). Investors who purchased Repare securities are encouraged to obtain additional infor...
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the fourth quarter and full year ended December 31, 2023. “2023 was a year of substantial progress ...
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
2024-02-26 19:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
The law firm of Kirby McInerney LLP is investigating potential claims against Repare Therapeutics Inc. (“Repare” or the “Company”) (NASDAQ: RPTX ). The investigation concerns whether Repare and/or certain of its officers have violated the federal securities law...
RP-1664 is a Potential First-in-Class, Selective, PLK4 Inhibitor Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the first patient has been dosed in the Company’s...
2024-02-12 17:45:24 ET More on Repare Therapeutics Seeking Alpha’s Quant Rating on Repare Therapeutics Historical earnings data for Repare Therapeutics Financial information for Repare Therapeutics Read the full article on Seeking Alpha For fur...
News, Short Squeeze, Breakout and More Instantly...
Repare Therapeutics Inc. Company Name:
RPTX Stock Symbol:
NASDAQ Market:
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the first patient has been dosed in the Company’s camonsertib monotherapy non-small cell lung cancer (NSCLC) expansion of th...
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to lunresertib in combination with camonsertib for t...
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare C...